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Abstract
We retrospectively reviewed a total of 257 stage I to IIIa lung adenocarcinoma after resection, tested them for
the epidermal growth factor receptor (EGFR) mutation, and analyzed the effect of perioperative treatment on
survival. The results showed that in patients with an EGFR mutation, adjuvant EGFR-tyrosine kinase inhibitor
monotherapy after complete resection signiﬁcantly prolongs disease-free survival compared with adjuvant
chemotherapy and/or radiotherapy.
Background: Adjuvant cisplatin-based chemotherapy improves nonesmall-cell lung cancer (NSCLC) 5-year survival
rates after resection. However, adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
efﬁcacy and the optimal adjuvant treatment are unclear. Patients and Methods: The clinical records of patients tested
for EGFR mutation after complete NSCLC resection were reviewed and tested for signiﬁcance; EGFR mutation and
adjuvant therapy effects on survival were assessed using univariate and Cox regression analyses. Results: We
enrolled 257 patients (stage I, 126; stage II-IIIa, 131); 138 had EGFR mutation. EGFR mutation status was unrelated to
recurrence (hazard ratio [HR], 0.83; 95% conﬁdence interval [CI], 0.572-1.204; P ¼ .326) or death (HR, 0.679; 95% CI,
0.406-1.136; P ¼ .14). Thirty-one patients with EGFR mutation received adjuvant EGFR-TKIs; most (87.1%) received
EGFR-TKI monotherapy. Patients who received adjuvant EGFR-TKIs had longer disease-free survival (DFS) than those
who did not (P ¼ .033) or received conventional adjuvant chemotherapy (P ¼ .038). Adjuvant EGFR-TKIs did not affect
overall survival (OS; P ¼ .258), although the recipients had better 3-year OS (92.5% vs. 81%). Eight patients who
received adjuvant EGFR-TKI developed disease recurrence, which occurred in 7 patients during adjuvant treatment. In
the adjuvant EGFR-TKI group patients with a primary tumor EGFR mutation, EGFR mutation in the corresponding
metastatic lymph nodes did not affect DFS, but patients who received EGFR-TKI after recurrence had longer
progression-free survival (P ¼ .087). Conclusion: In patients with an EGFR mutation, adjuvant EGFR-TKI monotherapy
after complete resection signiﬁcantly prolongs DFS compared with adjuvant chemotherapy and/or radiotherapy.
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Despite aggressive surgical management, stage I to IIIa none
small-cell lung cancer (NSCLC) has a low 5-year survival rate (73%-
24%) and a high recurrence rate.1,2 Adjuvant chemotherapy after
resection has always been considered an effective measure for
reducing the recurrence rate, hence improving the overall survival
(OS) rate. In 2003 to 2008, a number of large randomized
controlled trials that assessed the efﬁcacy of adjuvant chemotherapy
after surgical resection were reported. The results were consistent
in that adjuvant cisplatin-based chemotherapy improved survival,
with a 5-year absolute beneﬁt of 5.4% from chemotherapy, espe-
cially for stage II to IIIa patients (hazard ratio [HR], 0.83; 95%
conﬁdence interval [CI], 0.73-0.95).3-7 Recently, a meta-analysis of
15 randomized controlled trials of preoperative chemotherapy in
NSCLC yielded an absolute survival improvement of 5% at 5 years
(ie, from 40% to 45%).8 These ﬁndings indicate that in perioper-
ative therapy, neoadjuvant and adjuvant chemotherapy yield a
5-year beneﬁt of approximately 5%. To enhance the results of
therapy, further studies on adjuvant therapy are necessary. Over the
past 5 years, multiple phase III studies have proven that epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs),
which target the EGFR pathway, are superior to chemotherapy as
initial treatment for patients with the EGFR mutation and advanced
disease.9-13 In addition, the toxicity of adjuvant chemotherapy
causes low compliance rates (45%-73.8%), and chemotherapy
causes many more Grade 3 or 4 toxic effects compared with
EGFR-TKIs, neutropenia in particular. Thus, the high efﬁcacy and
low toxicity of EGFR-TKI therapy renders it a possible part of
adjuvant therapy after resection, or even allows it to challenge the
established status of chemotherapy.
Based on these ﬁndings, we retrospectively reviewed all cases of
stage I to IIIa lung adenocarcinoma after resection at our center,
tested them for an EGFR mutation, and analyzed their perioperative
treatment and recurrence to comprehensively assess the effect of
clinical and molecular characteristics on survival, and the clinical
outcome of patients after adjuvant therapy.
Patients and Methods
Patient Selection
We retrospectively reviewed records of all patients who under-
went surgery for lung adenocarcinoma and who were tested for the
EGFR mutation at Peking University (PKU) Cancer Hospital from
September 2004 to May 2013. All of the patients’ tumor, node,
metastases staging were identiﬁed according to the American Joint
Committee on Cancer guidelines, 7th edition.1 Patients with
pathological stage IIIb or IV disease were excluded. We also
excluded patients who did not meet complete resection (R0)
criteria. Complete resection was deﬁned as free resection margins
with systematic nodal dissection showing that the highest medias-
tinal node was negative, with no extracapsular nodal extension of
the tumor. Lobar, segmental, and subsegmental node resection was
performed for accurate N staging. Preoperative treatment, which
included neoadjuvant chemotherapy and targeted therapy, was
recorded. Platinum-based adjuvant chemotherapy was recom-
mended for patients with pathologic stage IIa to IIIa disease, and
high-risk stage Ib patients. Patients with pathologic mediastinal
lymph node metastasis (N2) also received local radiation after- Clinical Lung Cancer November 2015surgery. Based on physician or patient preference, or because of
poor Eastern Cooperative Oncology Group status, some patients
refused chemotherapy, opting for targeted therapy or only obser-
vation instead. Follow-up information was collected every 3 months
within 2 years after surgery, and every 6 months from 3 to 5 years.
When disease recurred, we collected treatment information,
including EGFR-TKIs as ﬁrst-line treatment for patients with an
EGFR mutation, together with chemotherapy or radiotherapy.
Response to treatment was evaluated according to the Response
Evaluation Criteria in Solid Tumors criteria. In addition, the
duration of adjuvant treatment after surgery and progression-free
survival (PFS) after disease recurrence in patients who received
EGFR-TKIs were recorded.
Epidermal Growth Factor Receptor Mutation Analysis
Before 2010, EGFR mutation testing was performed on
resected formalin-ﬁxed, parafﬁn-embedded (FFPE) lung cancer
tissue from patients with disease recurrence after surgery to
determine whether EGFR-TKIs could be used clinically. Testing
was performed using an ampliﬁed refractory mutation system
(ARMS) kit (Amoy Diagnostics, Xiamen, China). Analysis was
carried out as described in the kit operation instructions. Subse-
quently, EGFR mutation analysis was performed by the PKU
Cancer Hospital Department of Pathology, and gradually became
routine, and the testing method was switched to the TaqMan
PCR assay (Beijing ACCB Biotech Ltd, Beijing, China). The
method was performed as previously described.14 Brieﬂy, genomic
DNA was extracted from FFPE samples using a QIAamp DNA
FFPE Tissue Kit (Qiagen, Hilden, Germany). The 30 hotspot
mutations within exon 18 to 21 of the EGFR gene were examined
using a Human EGFR Mutation Qualitative Detection Kit
(Beijing ACCB Biotech Ltd, Beijing, China). Hydrolysable
ﬂuorescent probes were speciﬁcally designed to detect different
mutations (point mutations, insertions, deletions). The poly-
merase chain reaction (PCR) conditions were as follows: initial
denaturation at 95C for 10 minutes, followed by 40 cycles at
95C for 15 seconds and 60C for 1 minute.
In addition, in patients with an EGFR mutation and patholog-
ically conﬁrmed lymph node metastasis after surgery (N1 or N2),
additional mutation testing was performed on one of the corre-
sponding metastatic lymph nodes by an experienced pathologist to
conﬁrm the presence of tumor cells in the lymph nodes. Tumor
cells were microdissected and harvested from slides of metastatic
lymph nodes for DNA extraction.
Statistical Analysis
Statistical analysis was performed using patched SPSS 17.0 for
Windows (SPSS Inc, Chicago, IL). The relationship between the
presence of the EGFR mutation and clinical variables (age, sex,
smoking status, visceral pleural involvement, vascular invasion, node
status) was analyzed with the c2 or Fisher exact test for discrete
variables, and with the t test for continuous variables. The disease-
free survival (DFS) and OS of patients with mutant and wild type
EGFR were calculated using the KaplaneMeier method and
compared using the log-rank test. Cox regression analysis was
used to identify the effect of the covariates. Among the patients
with EGFR mutation, the same method was used to compare
Chao Lv et alconventional adjuvant chemotherapy and adjuvant EGFR-TKI
therapy. Results were considered signiﬁcant at P < .05.
Results
Patients and EGFR Mutation
Between September 2004 to May 2013, 1270 patients with
NSCLC underwent resection performed by the same surgical team.
Of these patients, 319 with adenocarcinoma were tested for the
EGFR mutation. After excluding patients with advanced disease and
incomplete resection, a ﬁnal cohort of 257 cases met the study
criteria (Figure 1). The patients’ clinical characteristics are listed in
Table 1.
This cohort consisted of 126 stage I (49%) and 131 stage II to
IIIa (51%) cases. Forty-two patients were tested for the EGFR
mutation using the ARMS method before 2010, whereas most of
the patients underwent surgery in the past 5 years from 2009 to
2013 (n ¼ 231; 89.9%). The EGFR mutation was observed in 138
cases (53.7%), and the mutant exons are listed in Table 2. There
was a signiﬁcant association between EGFR mutation and sex and
smoking status.
Treatment
Resection consisted of 4 pneumonectomies (1.6%), 9 bilo-
bectomies (3.5%), 227 lobectomies (88.3%), and 17 sub-
lobectomies (6.6%). One hundred and seventeen patients received
perioperative platinum-based chemotherapy: 91 received 4 cycles
(77.8%), 11 received 3 cycles (9.4%), 10 received 2 cycles (8.5%),Figure 1 Flow Chart of Screened Patients
Abbreviations: EGFR ¼ epidermal growth factor receptor; NSCLC ¼nonesmall-cell lung cancer; TKand 5 received 1 cycle (4.3%). Among the patients with an EGFR
mutation, 31 received adjuvant EGFR-TKIs for > 3 months within
2 months after surgery or after adjuvant chemotherapy. The median
and mean adjuvant EGFR-TKI treatment duration was 18 months
(range, 3-44 months) and 17.0  10.47 months, respectively. Of
the 31 patients who received adjuvant EGFR-TKIs, 27 received
EGFR-TKIs exclusively without adjuvant chemotherapy or radio-
therapy (87.1%). The EGFR-TKIs included geﬁtinib (n ¼ 14;
45.2%), erlotinib (n ¼ 6; 19.4%), and icotinib (Zhejiang Beta
Pharma Inc, Zhejiang, China) (n ¼ 11; 35.4%). The pathological
stage and adjuvant therapy are listed in Table 3.
Survival Analysis
The median follow-up time was 31 months (6-119 months). The
median DFS in patients with stage I, II, and IIIa disease was 54, 34,
and 19 months (P < .0001), respectively, and the 5-year OS rates
were 69.1%, 52.9%, and 37.9%, respectively. Univariate and
multivariate analysis of the entire cohort determined that only
pathologic stage was a prognostic factor for DFS and OS, and
EGFR mutation status, together with sex, age, and smoking status,
was not related to recurrence or death (Figure 2A and B and
Figure 3A and B).
From the 138 patients with an EGFR mutation, we selected 132
patients who harbored exon 19 deletion or exon 21 L858R, and
excluded those with exon 20 mutations. Among these patients,
30 received adjuvant EGFR-TKIs, 26 of whom did not receive
adjuvant chemotherapy or radiotherapy. KaplaneMeier survivalI ¼ tyrosine kinase inhibitor.
Clinical Lung Cancer November 2015 - e175
Table 1 Patient Characteristics and Correlation With an EGFR
Mutation
Variables
EGFR
Mutation
(n [ 138)
EGFR
Wild Type
(n [ 119) P
Sex .001
Male 44 64
Female 94 55
Age, Years 60.8  10.0 59.9  10.7 .496
Smoking <.001
Ever 27 53
Never 111 66
Performance Status .803
0-1 128 112
2þ 10 7
Visceral Pleural Involvement .098
Yes 88 63
No 50 56
Vascular Invasion 1.000
Yes 25 22
No 113 97
Stage .281
I 69 57
II 21 27
IIIa 48 35
Lymph Node Metastasis .900
N0 76 67
N1-2 62 52
Lymph Node Metastasis
N0-1 100 91 .478
N2 38 28
EGFR Testing .176
ARMS 27 15
TaqMan PCR assay 111 104
Abbreviations: ARMS ¼ ampliﬁed refractory mutation system; EGFR ¼ epidermal growth factor
receptor.
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e176analysis revealed that patients who received adjuvant EGFR-TKIs
had longer DFS than those who did not (P ¼ .033; Figure 3C).
Cox regression analysis also conﬁrmed that pathologic stage andTable 2 Overall Frequency of Mutant Exons
Patient n
Mutant Exon
Exon 18 4
Exon 19 58
Exon 20 0
Exon 21 70
Complex Mutation
Exon 18 and 21 3
Exon 19 and 21 1
Exon 20 and 21 2
- Clinical Lung Cancer November 2015adjuvant EGFR-TKIs were signiﬁcant prognostic factors for recur-
rence (Figure 2C). To compare the effect of adjuvant chemotherapy
and EGFR-TKIs on survival, we selected all cases with pathologic
stage II to IIIa disease who required and received adjuvant therapy
after surgery, and excluded 4 patients who did not receive any
therapy. Univariate and multivariate analyses indicated that in these
patients, adjuvant EGFR-TKIs signiﬁcantly prolonged DFS
compared with conventional adjuvant chemotherapy (P ¼ .038,
P¼ .047, respectively; Figure 2D and Figure 3D). Adjuvant EGFR-
TKI therapy did not affect the OS of the 2 groups (P ¼ .258;
Figure 3E), but the adjuvant EGFR-TKI group had better 3-year
OS (92.5% vs. 81%).
Recurrence
In the overall patient cohort, 118 patients developed recurrence
during the follow-up period, of whom 64 (54.2%) harbored an
EGFR mutation. Of these 64 patients, 8 received adjuvant
EGFR-TKIs; recurrence occurred among 7 of them during adjuvant
EGFR-TKI therapy. The information of these patients is listed in
Table 4. Of the remaining 56 patients, 47 received EGFR-TKIs,
40 of whom were evaluated for response to treatment. Twenty-six
patients had a partial response (65%), 8 had stable disease (20%),
and 6 had progressive disease (15%); the median PFS of these
patients was 14 months (95% CI, 4.431-23.569).
Epidermal Growth Factor Receptor Mutation in
Metastatic Lymph Nodes
We tested 50 patients with stage II to IIIa disease who had
primary tumor EGFR mutation or lymph node EGFR mutation.
Of these patients, 20 received adjuvant EGFR-TKIs, 28 received
EGFR-TKIs after disease recurrence, and 2 did not receive
EGFR-TKIs even after disease recurrence. The EGFR mutation was
detected in 31 patients (62%), and comprised 15 exon 19 deletions
(48.4%), 15 exon 21 mutations (13 L858R and 2 L861Q; 48.4%),
and 1 exon 18 mutation (3.2%). In the 20 patients who were
treated with adjuvant EGFR-TKIs, lymph node EGFR mutation
was not a prognostic factor for DFS or OS (P ¼ .903, P ¼ .834,
respectively). Among the patients treated with EGFR-TKIs
after recurrence, 20 were evaluated for response to treatment, and
there was no signiﬁcant correlation between lymph node EGFR
mutation and response to EGFR-TKIs (objective response rate:
66.7% vs. 62.5%; P ¼ .848). Although the patients with lymph
node EGFR mutation had better median PFS (median PFS time
was not reached) than those without lymph node EGFR mutation
(6.0  2.1 months); this difference was not signiﬁcant (P ¼ .087;
Figure 3F).
Discussion
In this retrospective study we comprehensively evaluated
the EGFR mutation status of patients with adenocarcinoma
who had undergone surgery and their survival after adjuvant
therapy. All surgeries were performed by the same surgical
team, and complete resection was required. Only a few patients
(8.2%) in this cohort underwent pneumonectomy or sub-
lobectomy. All of the procedures were carried out to minimize
the potential effect on survival resulting from surgery. In all
patients reviewed, there was a high EGFR mutation frequency of
Table 3 Adjuvant Therapy According to Disease Stage and Mutation Status
Adjuvant
Therapy
Stage I (n [ 126) Stage II (n [ 48) Stage IIIa (n [ 83)
M
(n [ 69)
W
(n [ 57)
M
(n [ 21)
W
(n [ 27)
M
(n [ 48)
W
(n [ 35)
N (n [ 112) 55 44 0 6 4 3
C (n [ 78) 6 13 16 21 9 13
C D R (n [ 36) 0 0 0 0 17 19
T (n [ 27) 8 0 4 0 15 0
C D T (n [ 1) 0 0 1 0 0 0
R D T (n [ 1) 0 0 0 0 1 0
C D R D T (n [ 2) 0 0 0 0 2 0
Abbreviations: C ¼ perioperative chemotherapy; M ¼ epidermal growth factor receptor mutation; N ¼ no adjuvant therapy; R ¼ adjuvant radiotherapy; T ¼ adjuvant epidermal growth factor receptor-
tyrosine kinase inhibitor treatment; W ¼ wild type epidermal growth factor receptor.
Chao Lv et al53.7%, which is similar to the results of the Asian PIONEER
(A Molecular Epidemiology Study in Asian Patients with
Advanced NSCLC of Adenocarcinoma Histology to Assess
EGFR Mutation Status) study (NCT01185314; 51.4%).15Figure 2 Forest Plots of Hazard Ratios (HRs) for Overall DFS (A) an
Mutation (C); and Stage II to IIIa Patients With EGFR Muta
Abbreviations: EGFR ¼ epidermal growth factor receptor; TKI ¼ tyrosine kinase inhibitor.Although studies reported by Massachusetts General Hospital
and Memorial Sloan-Kettering Cancer Center (MSKCC) proved
that EGFR mutation has a signiﬁcant effect on survival
after surgical resection,16,17 we did not observe the role of thisd OS (B); Forest Plots of HRs for DFS in All Patients With EGFR
tion (D)
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Figure 3 KaplaneMeier Curves of Disease-Free Survival (DFS) (A) and Overall Survival (OS) (B) of All Patients in the Mutant and Wild
Type Epidermal Growth Factor Receptor (EGFR) Groups. KaplaneMeier Curves of DFS of 132 Patients in the Adjuvant and
Nonadjuvant EGFR-Tyrosine Kinase Inhibitor (TKI) Groups Harboring Exon 19 and 21 Mutations (C), and of DFS in 61 Patients
With Stage II to IIIa Disease in the Adjuvant EGFR-TKI and Adjuvant Chemotherapy Groups Harboring Exon 19 and 21
Mutations (D). KaplaneMeier Curves of OS of 132 Patients in the Adjuvant and Nonadjuvant EGFR-TKI Groups Harboring
Exon 19 and 21 Mutations (E). KaplaneMeier Curves of Progression-Free Survival (PFS) of 23 Patients With EGFR Mutations
Who Were Treated With EGFR-TKIs After Recurrence (F)
Abbreviation: LN ¼ lymph node.
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e178prognostic factor in DFS or OS, even though the 3-year OS of
the mutant EGFR group was numerically better than that of the
wild type EGFR group (82.4% vs. 77.7%). The same results
were reported in Japan, Korea, and Taiwan.18-20 It is possible
that the high EGFR mutation frequency in Asia is a reason for
this inconsistency.- Clinical Lung Cancer November 2015A series of randomized controlled trials and retrospective studies
have been carried out to evaluate the effect of adjuvant EGFR-TKIs
after complete resection of lung cancer. Although the BR.19 study,
which was designed for administration of geﬁtinib versus placebo
but did not enrich for patients with an EGFR mutation, did not
answer the question regarding the efﬁcacy of adjuvant geﬁtinib,21
Table 4 Clinical Data of Patients With Recurrent Disease Treated with Adjuvant EGFR-TKIs
Number Sex Stage Exon
Duration of Adjuvant
EGFR-TKI Therapy
(Months)
Disease Recurred
During Adjuvant
EGFR-TKI Therapy
Site of
Recurrence
DFS,
Months
1 F II 21 18 Yes Lung 19
2 M IIIa 19 20 Yes Lymph node 21
3 M IIIa 19 3 Yes Lymph node 4
4 M IIIa 21 3 Yes Lung 4
5 F IIIa 19 21 Yes Lung 22
6 F IIIa 19 15 Yes Brain 19
7 M IIIa 19 16 Yes Lung 18
8 F IIIa 21 18 No Brain and bone 24
Abbreviations: DFS ¼ disease-free survival; EGFR-TKI ¼ epidermal growth factor receptor tyrosine kinase inhibitor; F ¼ female; M ¼ male.
Chao Lv et al2 retrospective studies conducted by MSKCC demonstrated
improved DFS resulting from adjuvant EGFR-TKIs.17,22 Another
prospective trial published in 2014 proved that 6-month adminis-
tration of geﬁtinib after pemetrexed/carboplatin adjuvant therapy
improved DFS signiﬁcantly.23 In the subset analysis of the
RADIANT (Randomized Double-blind Trial in Adjuvant NSCLC
with Tarceva) trial, patients with an EGFR mutation treated with
adjuvant erlotinib tended to have better DFS, although this was
not statistically signiﬁcant.24 The SELECT (Surgically Resected
EGFR Mutant Lung Cancer with Adjuvant Erlotinib Cancer
Treatment) trial also proved that adjuvant erlotinib resulted in an
improved 2-year DFS compared with historical genotype-matched
control subjects (89% vs. 76%).25 Last year, the ALCHEMIST
(Adjuvant Lung Cancer Enrichment Marker Identiﬁcation and
Sequencing Trials) study was launched to determine whether
adjuvant TKIs could prevent disease recurrence and prolong survival
according to different mutations.26 Because adjuvant EGFR-TKIs
might be effective for improving the DFS or even OS of patients
who harbor an EGFR mutation, the following 4 questions should
be answered.
First, is EGFR-TKI monotherapy after resection sufﬁcient to
replace standard adjuvant therapies for patients with an EGFR
mutation? In previous studies, EGFR-TKIs were administered after
4 cycles of cisplatin-based chemotherapy and radiotherapy (N2)
after surgery.17,23 In our study, only 4 of 31 patients who received
adjuvant EGFR-TKIs completed conventional adjuvant chemo-
therapy and/or radiotherapy, which differs from previous ﬁndings.
However, the results, including those for patients with stage II to
IIIa disease, still showed that EGFR-TKIs alone prolonged DFS
signiﬁcantly compared with adjuvant chemotherapy and/or radio-
therapy, which indicates that EGFR-TKI monotherapy might
substitute or even supersede standard adjuvant therapies for patients
with EGFR mutation as far as recurrence is concerned. Prospective
studies such as CTONG (Chinese Thoracic Oncology Group)
1104 (NCT01405079), which was designed to compare geﬁtinib
monotherapy with vinorelbine/cisplatin as adjuvant therapy for
patients with stage II to IIIa disease and an EGFR mutation, are
required to conﬁrm this ﬁnding.
Second, if EGFR-TKIs are used in adjuvant therapy, will
chemotherapy after resection be necessary for patients with stage Ib
to IIIa disease and EGFR mutation? Although the pooled analysisby the LACE Collaborative Group reported a 5-year absolute
beneﬁt of 5.4% from adjuvant chemotherapy, whether patients with
an EGFR mutation can beneﬁt from chemotherapy is controversial.
Some have found that adjuvant chemotherapy signiﬁcantly prolongs
survival among patients with wild type EGFR status rather than
patients with mutant EGFR.27 A retrospective study also reported
that in N2-positive NSCLC, an EGFR mutation was a signiﬁcant
prognostic factor for higher risk of distant recurrence/progression
than wild type EGFR after neoadjuvant chemoradiotherapy after
surgery.28 Another study revealed that in N2 patients with stage
IIIa disease and EGFR mutation, the observation group had even
longer median DFS (49 vs. 30 months; P ¼ .195) and OS (59 vs.
33 months; P ¼ .050) than the adjuvant chemotherapy group after
resection.29 Recently, the NCT01017874 trial reported that ﬁrst-
line pemetrexed with cisplatin followed by geﬁtinib maintenance
therapy resulted in similar PFS with geﬁtinib monotherapy in
advanced nonsquamous lung cancer with EGFR mutation (HR,
0.83; P ¼ .585).30 Therefore, a prospective trial to compare
chemotherapy followed by EGFR-TKI treatment with EGFR-TKI
monotherapy as adjuvant therapy is necessary to evaluate the ef-
fect of chemotherapy on DFS in patients with an EGFR mutation.
Third, what is the optimal duration of adjuvant EGFR-TKI
treatment? In our study, 8 patients who received EGFR-TKIs had
disease recurrence after surgery, 7 of which occurred during adju-
vant EGFR-TKI treatment, which indicated that EGFR-TKI
resistance, rather than inadequate EGFR-TKI administration
duration, resulted in disease recurrence in these patients. Of the
7 patients, 2 had disease recurrence shortly after resection, which
might have resulted from intrinsic resistance, and the other 5 pa-
tients received EGFR-TKIs for > 15 months before disease recur-
rence occurred. In a prospective study on 6-month administration
of adjuvant geﬁtinib, 8 patients with disease recurrence received
further geﬁtinib treatment and 4 patients had objective response,
which indicated that the duration of adjuvant geﬁtinib treatment
was insufﬁcient.23 The SELECT trial also suggested longer duration
of adjuvant treatment (> 2 years). It has been reported that in
patients with advanced disease and EGFR mutation, ﬁrst-line
EGFR-TKIs resulted in a median PFS of 9.5 to 13.1 months,10-13
which was considered the median time to resistance. In our
study, the median and mean duration of adjuvant EGFR-TKI
treatment was approximately 1.5 years (18 months andClinical Lung Cancer November 2015 - e179
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tion of administration should be at least > 1 year, thus exceeding the
median time to EGFR-TKI resistance. We are currently conducting
a multicenter phase II study (NCT01929200) at our hospital to
evaluate the optimal duration of adjuvant EGFR-TKI treatment.
Finally, what kind of patients would be candidates for adjuvant
EGFR-TKI treatment? Although EGFR-TKIs are effective in
patients who harbor an EGFR mutation, with a response rate of
71.2% to 83%, approximately 20% of patients with an EGFR
mutation have intrinsic resistance to this treatment.10-12 One of the
possible mechanisms of primary resistance is tumor heterogeneity.
Previous studies have reported that intratumoral heterogeneity of an
EGFR mutation resulted in reduced response to EGFR-TKIs,31
whereas heterogeneity between the primary tumor and matched
metastatic tumor was related to a mixed response to EGFR-TKIs.32
In our study, we additionally tested mutation in the metastatic
lymph nodes of patients with an EGFR mutation, and detected a
discordance rate of 38%. However, we did not observe a signiﬁcant
difference between DFS in the adjuvant EGFR-TKI group. One
reason for this result is that besides adjuvant therapy, disease
recurrence is also inﬂuenced by other genome-regulated tumor
biological features, especially when the number of patients in a
study is small. In the group of patients treated with EGFR-TKI who
had disease recurrence, an EGFR mutation in the lymph node was
not a signiﬁcant factor in the response to EGFR-TKIs. However, we
observed a tendency toward longer PFS among patients with an
EGFR mutation in the corresponding metastatic lymph nodes. This
indicates that EGFR mutation heterogeneity might have some
effect but is not the crucial factor for intrinsic EGFR-TKI resistance,
and further study on multiple gene detection that includes the
BIM (BCL2-like 11) deletion polymorphism is required to identify
individuals who are unsuitable for adjuvant EGFR-TKI treatment
because of intrinsic resistance.33
Conclusion
In this single-center retrospective study we assessed EGFR mu-
tation status and survival after adjuvant therapy to investigate the
optimal adjuvant therapeutic modality after surgical resection.
Although the short follow-up period and small number of patients
treated with adjuvant EGFR-TKIs are potential limitations, the
results are promising. To conﬁrm our results, a series of the
previously mentioned ongoing randomized controlled trials are
necessary and expected, which would determine the effect of
adjuvant EGFR-TKIs on survival and potentially identify the
cohort of patients who would beneﬁt from this treatment modality.
Clinical Practice Points
 In perioperative therapy, neoadjuvant and adjuvant chemo-
therapy yield a 5-year beneﬁt of approximately 5%. Adjuvant
EGFR-TKI efﬁcacy and the optimal adjuvant treatment are
unclear.
 We retrospectively reviewed the perioperative treatment and
recurrence of 257 patients (stage I, 126; stage II-IIIa, 131) tested
for an EGFR mutation after complete NSCLC resection, and
found that patients who received adjuvant EGFR-TKIs had
longer DFS than those who did not (P ¼ .033) or received
conventional adjuvant chemotherapy (P ¼ .038). Adjuvant- Clinical Lung Cancer November 2015EGFR-TKI treatment did not affect OS (P ¼ .258), although
the recipients had better 3-year OS (92.5% vs. 81%). Moreover,
an EGFR mutation in the corresponding metastatic lymph
nodes did not affect DFS for patients who received adjuvant
EGFR-TKI treatment, but showed longer PFS for those who
received EGFR-TKI treatment after disease recurrence (P¼ .087).
 The results of adjuvant EGFR-TKI monotherapy on DFS for
patients with an EGFR mutation are promising. A series of the
ongoing randomized controlled trials are necessary to conﬁrm the
effect of adjuvant EGFR-TKI treatment on survival, determine
the optimal duration of adjuvant EGFR-TKI treatment, and
identify the cohort of patients who would beneﬁt from this
treatment modality.Acknowledgments
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